Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621886 | 0.88 | RAB9A (0.47) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL8616512 | 0.73 | ALDH1A1 (0.67) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL11258013 | 0.73 | EPHX1 (0.72) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL1622164 | 0.72 | KMT2A (0.66) | EPHX1ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL1620406 | 0.71 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL5443717 | 0.71 | ALDH1A1 (0.84) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL8612464 | 0.70 | EPHX1 (0.77) | EPHX1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1620804 | 0.70 | EPHX1 (0.71) | EPHX1ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1622029 | 0.69 | EPHX1 (0.61) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL11653864 | 0.69 | PLK1 (0.68) | EPHX1ALDH1A1SMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9603848-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8633186-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8541421-B2 | Methods of enhancing sweet taste of compositions using substituted thieno{2,3-D}pyrimidines | SENOMYX INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2573559-A1 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2568287-A2 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20110230502-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2062050-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | Senomyx, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230502-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | EPHX1 4057/4885ALDH1A1 4103/4885SMN1; SMN2 4716/4885 |
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | EPHX1 4057/4885ALDH1A1 4103/4885SMN1; SMN2 4716/4885 |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | EPHX1 4470/4885ALDH1A1 4242/4885SMN1; SMN2 4713/4885 |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | EPHX1 4057/4885ALDH1A1 4103/4885SMN1; SMN2 4716/4885 |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | EPHX1 4470/4885ALDH1A1 4242/4885SMN1; SMN2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.